Identification of 14,20-dihydroxy-docosahexaenoic acid as a novel anti-inflammatory metabolite | Zendy

Yoshiyuki Yokokura | Zendy; Yosuke Isobe | Zendy; Shinnosuke Matsueda | Zendy; Ryo Iwamoto | Zendy; Tomomi Goto | Zendy; Takeshi Yoshioka | Zendy; Daisuke Urabe | Zendy; Masayuki Inoue | Zendy; Hiroyuki Arai | Zendy; Makoto Arita | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Identification of 14,20-dihydroxy-docosahexaenoic acid as a novel anti-inflammatory metabolite

Author(s) -

Yoshiyuki Yokokura,

Yosuke Isobe,

Shinnosuke Matsueda,

Ryo Iwamoto,

Tomomi Goto,

Takeshi Yoshioka,

Daisuke Urabe,

Masayuki Inoue,

Hiroyuki Arai,

Makoto Arita

Publication year - 2014

Publication title -

the journal of biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.28

H-Index - 115

eISSN - 1756-2651

pISSN - 0021-924X

DOI - 10.1093/jb/mvu044

Subject(s) - docosahexaenoic acid , metabolite , chemistry , biochemistry , zymosan , in vivo , anti inflammatory , arachidonic acid , pharmacology , fatty acid , polyunsaturated fatty acid , in vitro , biology , enzyme , microbiology and biotechnology

Docosahexaenoic acid (DHA) exhibits anti-inflammatory activity related to some of its oxygenated metabolites, such as D-series resolvins, protectin and maresin. Here, we analysed the lipids in inflammatory exudates using liquid chromatography-tandem mass spectrometry and identified a novel DHA metabolite, 14,20-dihydroxy-DHA (14,20-diHDHA) and showed that it is biosynthesized by eosinophils through the 12/15-lipoxygenase pathway. The chemical structure of the dominant 14,20-diHDHA isomer, which is endogenously biosynthesized by eosinophils, was identified as 14S,20R-diHDHA using chemically synthesized stereoisomers. Nanogram doses of 14,20-diHDHA displayed a potent anti-inflammatory action by limiting neutrophil infiltration in zymosan-induced peritonitis. The in vivo formation and potent anti-inflammatory action of 14,20-diHDHA may contribute to the protective effects of DHA.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research